急性冠症候群後のフォローアップ冠動脈造影時における低比重リポ蛋白コレステロール値と再治療の関連:症例対照研究

  • 奥川 寛
    社会福祉法人京都社会事業財団京都桂病院薬剤科
  • 土手 賢史
    社会福祉法人京都社会事業財団京都桂病院薬剤科
  • 堀内 望
    社会福祉法人京都社会事業財団京都桂病院薬剤科
  • 小林 由佳
    社会福祉法人京都社会事業財団京都桂病院薬剤科

書誌事項

タイトル別名
  • Association between Lipid Level and Revascularization at Routine Coronary Angiography Follow-up among Patients with Acute Coronary Syndrome: A Case-control Study

この論文をさがす

抄録

<p>Among acute coronary syndrome (ACS) patients, it is recommended that a low-density lipoprotein cholesterol (LDL-C) level of < 70 mg/dL is achieved using statin therapy for secondary prevention. However, the timeframe to achieve this lipid level target is unknown. Therefore, the aim of this study was to investigate the association between lipid level and revascularization at routine coronary angiography follow-up performed at six months or later from the first ACS onset (CAG-6M). We conducted a case-control study that included 82 ACS patients at Kyoto-Katsura Hospital between January 2018 and December 2019. Eligible patients were divided either into the group with revascularization at CAG-6M or those without, i.e., case (n = 29) and control (n = 53), respectively. CAG-6M was performed at about eight months after the first ACS onset. Although the mean LDL-C level at CAG-6M was 98.2 (SD 24.6) mg/dL in the case group and 91.5 (SD 29.4) mg/dL in the control (P = 0.3) group, the prevalence of patients who had achieved the target LDL-C levels at CAG-6M was 3.4% in the case group and 30.2% in the control (P < 0.05) group. After conducting a multivariate analysis in which revascularization at CAG-6M was considered the objective variable and age, sex, lifestyle diseases, and the target LDL-C level were considered as covariates, only achievement of the target LDL-C level was found to be an independent risk factor. In conclusion, our results suggest that the target LDL-C level should be achieved within about eight months after the first ACS onset to prevent revascularization.</p>

収録刊行物

  • 医療薬学

    医療薬学 48 (3), 113-120, 2022-03-10

    一般社団法人日本医療薬学会

参考文献 (22)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ